| 摘要 |
<p>The present invention relates to a method for screening an agent for treating a degenerative neurological disease which decreases formation of fused in sarcoma (FUS) aggregation by inhibiting combination of a FUS mutant and a protein arginine methyltransferase 1 (PRMT1) protein, wherein the method comprises the steps of: (a) expressing a FUS mutant protein in cells; (b) treating the cells with oxidative stress causing materials; (c) contacting the cells with a test material; and (d) screening an agent, which inhibits combination of a FUS mutant and a PRMT1 protein and decreases formation of FUS aggregation, as an agent for treating a degenerative neurological disease in comparison with a control group having the untreated test material.</p> |
